FDA revises compliance guide on pre-approval inspections - RAPS
FDA revised its compliance guide on pre-approval inspections, emphasizing cGMP compliance and potential for more rigorous inspections before drug approval.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 23, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; next inspection could occur at any time.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA updated its compliance policy guide (CPG) for pre-approval inspections, clarifying that inspections will focus on cGMP compliance and may be conducted earlier in the review process. The revision signals increased scrutiny and potential delays if deficiencies are found.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review and update cGMP documentation and quality systems to ensure readiness for pre-approval inspections. Ensure all manufacturing processes and facilities are compliant with current FDA expectations.
Deadline
Immediately; next inspection could occur at any time.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Order: Francis Esteban Matos: Final Debarment
- FDA Issues Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities in Pending Applications - ArentFox Schiff
- Pay(or) Attention, Drug and Device Makers: FDA’s New Guidance for Talking to Health Plans - ArentFox Schiff
- Revocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages
- Proposal to Revoke the Color Additive Listing for Use of Citrus Red No. 2 on the Skins of Mature Oranges